Pyxis Oncology, Inc. — Director's Dealing 2023

Dec 29, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Pyxis Oncology, Inc. (PYXS)
CIK: 0001782223
Period of Report: 2023-12-29

Reporting Person: Kobayashi Ken (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-12-29	Stock Option (Right to Buy)	$1.80	A	443514	Acquired	2033-12-29	Common Stock (443514)	Direct
2023-12-29	Stock Option (Right to Buy)	$1.80	A	110878	Acquired	2033-12-29	Common Stock (110878)	Direct

Footnotes

F1: The shares subject to this option will vest over four years, with 25% vesting on November 27, 2024 and the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued employment through the applicable vesting dates.

F2: The shares subject to this option will vest upon the achievement of certain clinical milestones related to data disclosure for PYX-201.